Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab

Conclusion: Pseudo progression is only seen in a small part of patients treated with immunotherapy. With little tumor burden a treatment continuation can be feasible. Also patients who are not considered fit for second line chemotherapy may continue treatment. Aggressive tumor growth or high tumor load should stay a domain of conventional second line chemotherapy.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: 11.1 Lung Cancer Source Type: research